Microcap biotech firm Neuralstem (CUR +0.6%) says the FDA has signed off for the company to...

|By:, SA News Editor

Microcap biotech firm Neuralstem (CUR +0.6%) says the FDA has signed off for the company to advance to Phase Ib in the ongoing clinical trial of its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder.